Publication & Citation Trends
Publications
17 total
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189 OA
Cited by 35
Semantic Scholar
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial PDF
Cited by 3,287
OpenAlex
Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study
Cited by 23
OpenAlex
PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 OA
Cited by 3
Semantic Scholar
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer PDF
Cited by 6,504
OpenAlex
Il marketing applicato al settore culturale: il caso del MoMA di New York
Cited by 0
Semantic Scholar
Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Cited by 11
Semantic Scholar
P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients OA
Cited by 17
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(7)
Lung Cancer Treatments and Mutations
(7)
Brain Metastases and Treatment
(3)
PARP inhibition in cancer therapy
(3)
Lung Cancer Research Studies
(3)
Affiliations
Université de Sherbrooke
Hôpital Charles-Le Moyne
Azienda Ospedaliero Universitaria Ospedali Riuniti
Santé Montérégie
Institute on Aging